In addition, Le et al. demonstrated that anti-PD-1 antibody-treated patients with mismatch repair-deficient colorectal cancer showed a higher immune-related objective response rate and immune-related PFS rate than patients with mismatch repair-proficient colorectal cancer [74]. This evidence concerns the gene PDCD1 and colorectal cancer.